One slide in the 18/06/2021 presentation shows the key market size (USA CAN EU5 AUS) as 71 million plus. Why is Japan never mentioned as it would have a market of 10 to 15 million. Also there would be middle class and wealthier people in China and India (and other places) who would be potential customers. Will PAR get access to these markets with the present strategy (ie EMA and FDA approval) or are these markets covered by separate regulating bodies.
MST - Presentation 17th June 2021, page-35
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 19.5¢ | $83.07K | 414.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 249283 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 81312 | 7 |
View Market Depth
| Last trade - 14.50pm 16/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |